Annual EBITDA
-$18.24 M
+$90.25 M+83.19%
December 1, 2024
Summary
- As of March 13, 2025, FULC annual EBITDA is -$18.24 million, with the most recent change of +$90.25 million (+83.19%) on December 1, 2024.
- During the last 3 years, FULC annual EBITDA has risen by +$60.30 million (+76.77%).
- FULC annual EBITDA is now at all-time high.
Performance
FULC EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$19.06 M
+$3.63 M+16.01%
December 31, 2024
Summary
- As of March 13, 2025, FULC quarterly EBITDA is -$19.06 million, with the most recent change of +$3.63 million (+16.01%) on December 31, 2024.
- Over the past year, FULC quarterly EBITDA has increased by +$8.42 million (+30.65%).
- FULC quarterly EBITDA is now -136.05% below its all-time high of $52.87 million, reached on June 30, 2024.
Performance
FULC Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$18.24 M
+$8.42 M+31.59%
December 31, 2024
Summary
- As of March 13, 2025, FULC TTM EBITDA is -$18.24 million, with the most recent change of +$8.42 million (+31.59%) on December 31, 2024.
- Over the past year, FULC TTM EBITDA has increased by +$90.25 million (+83.19%).
- FULC TTM EBITDA is now -155.62% below its all-time high of -$7.14 million, reached on March 31, 2018.
Performance
FULC TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
FULC EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +83.2% | +30.6% | +83.2% |
| 3 y3 years | +76.8% | +30.6% | +83.2% |
| 5 y5 years | +77.8% | +30.6% | +83.2% |
FULC EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +83.4% | -136.1% | +43.2% | at high | +83.7% |
| 5 y | 5-year | at high | +83.4% | -136.1% | +43.2% | at high | +83.7% |
| alltime | all time | at high | +83.4% | -136.1% | +48.1% | -155.6% | +83.7% |
Fulcrum Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | - | -$19.06 M(-16.0%) | -$18.24 M(-31.6%) |
| Dec 2024 | -$18.24 M(-83.2%) | - | - |
| Sep 2024 | - | -$22.69 M(-142.9%) | -$26.66 M(-13.6%) |
| Jun 2024 | - | $52.87 M(-280.1%) | -$30.88 M(-72.0%) |
| Mar 2024 | - | -$29.36 M(+6.8%) | -$110.47 M(+1.8%) |
| Dec 2023 | -$108.49 M(-1.1%) | -$27.48 M(+2.1%) | -$108.49 M(+0.1%) |
| Sep 2023 | - | -$26.91 M(+0.7%) | -$108.43 M(+3.5%) |
| Jun 2023 | - | -$26.73 M(-2.4%) | -$104.80 M(-6.1%) |
| Mar 2023 | - | -$27.37 M(-0.2%) | -$111.63 M(+1.7%) |
| Dec 2022 | -$109.72 M(+39.7%) | -$27.42 M(+17.8%) | -$109.72 M(+4.3%) |
| Sep 2022 | - | -$23.28 M(-30.6%) | -$105.24 M(+3.1%) |
| Jun 2022 | - | -$33.56 M(+31.8%) | -$102.11 M(+16.6%) |
| Mar 2022 | - | -$25.46 M(+11.0%) | -$87.56 M(+11.5%) |
| Dec 2021 | -$78.54 M | -$22.94 M(+13.8%) | -$78.54 M(+8.1%) |
| Sep 2021 | - | -$20.15 M(+6.0%) | -$72.66 M(+2.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$19.01 M(+15.6%) | -$71.05 M(+5.4%) |
| Mar 2021 | - | -$16.44 M(-3.6%) | -$67.42 M(-2.6%) |
| Dec 2020 | -$69.23 M(-15.7%) | -$17.05 M(-8.1%) | -$69.23 M(+1.6%) |
| Sep 2020 | - | -$18.55 M(+20.7%) | -$68.15 M(+3.1%) |
| Jun 2020 | - | -$15.37 M(-15.8%) | -$66.09 M(+3.8%) |
| Mar 2020 | - | -$18.26 M(+14.3%) | -$63.70 M(-22.5%) |
| Dec 2019 | -$82.16 M(+155.5%) | -$15.97 M(-3.1%) | -$82.16 M(+9.6%) |
| Sep 2019 | - | -$16.49 M(+27.0%) | -$74.94 M(+11.7%) |
| Jun 2019 | - | -$12.98 M(-64.7%) | -$67.07 M(+8.6%) |
| Mar 2019 | - | -$36.72 M(+320.1%) | -$61.74 M(+92.0%) |
| Dec 2018 | -$32.15 M(+44.3%) | -$8.74 M(+1.3%) | -$32.15 M(+37.3%) |
| Sep 2018 | - | -$8.63 M(+12.9%) | -$23.41 M(+58.4%) |
| Jun 2018 | - | -$7.65 M(+7.1%) | -$14.78 M(+107.1%) |
| Mar 2018 | - | -$7.14 M | -$7.14 M |
| Dec 2017 | -$22.28 M | - | - |
FAQ
- What is Fulcrum Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Fulcrum Therapeutics?
- What is Fulcrum Therapeutics annual EBITDA year-on-year change?
- What is Fulcrum Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Fulcrum Therapeutics?
- What is Fulcrum Therapeutics quarterly EBITDA year-on-year change?
- What is Fulcrum Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Fulcrum Therapeutics?
- What is Fulcrum Therapeutics TTM EBITDA year-on-year change?
What is Fulcrum Therapeutics annual EBITDA?
The current annual EBITDA of FULC is -$18.24 M
What is the all time high annual EBITDA for Fulcrum Therapeutics?
Fulcrum Therapeutics all-time high annual EBITDA is -$18.24 M
What is Fulcrum Therapeutics annual EBITDA year-on-year change?
Over the past year, FULC annual EBITDA has changed by +$90.25 M (+83.19%)
What is Fulcrum Therapeutics quarterly EBITDA?
The current quarterly EBITDA of FULC is -$19.06 M
What is the all time high quarterly EBITDA for Fulcrum Therapeutics?
Fulcrum Therapeutics all-time high quarterly EBITDA is $52.87 M
What is Fulcrum Therapeutics quarterly EBITDA year-on-year change?
Over the past year, FULC quarterly EBITDA has changed by +$8.42 M (+30.65%)
What is Fulcrum Therapeutics TTM EBITDA?
The current TTM EBITDA of FULC is -$18.24 M
What is the all time high TTM EBITDA for Fulcrum Therapeutics?
Fulcrum Therapeutics all-time high TTM EBITDA is -$7.14 M
What is Fulcrum Therapeutics TTM EBITDA year-on-year change?
Over the past year, FULC TTM EBITDA has changed by +$90.25 M (+83.19%)